Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Chronic Heart Failure

  Free Subscription

Articles published in J Mol Cell Cardiol

Retrieve available abstracts of 61 articles:
HTML format

Single Articles

    March 2023
  1. FUJII S, Kobayashi S, Chang Y, Nawata J, et al
    RyR2-targeting therapy prevents left ventricular remodeling and ventricular tachycardia in post-infarction heart failure.
    J Mol Cell Cardiol. 2023 Mar 22:S0022-2828(23)00052.
    PubMed     Abstract available

    January 2023
  2. ZHANG J, Song Y, Li Y, Lin HB, et al
    Iron homeostasis in the heart: Molecular mechanisms and pharmacological implications.
    J Mol Cell Cardiol. 2023;174:15-24.
    PubMed     Abstract available

  3. KHALILIMEYBODI A, Riaz M, Campbell SG, Omens JH, et al
    Signaling network model of cardiomyocyte morphological changes in familial cardiomyopathy.
    J Mol Cell Cardiol. 2023;174:1-14.
    PubMed     Abstract available

    December 2022
  4. ABOUMSALLEM JP, Shi C, De Wit S, Markousis-Mavrogenis G, et al
    Multi-omics analyses identify molecular signatures with prognostic values in different heart failure aetiologies.
    J Mol Cell Cardiol. 2022;175:13-28.
    PubMed     Abstract available

  5. DELBRIDGE LMD, Bell JR, Weeks KL, Raaijmakers AJA, et al
    HFpEF etiology - Can focus on sex-specific mechanisms deliver insights for all?
    J Mol Cell Cardiol. 2022;173:71-72.

  6. NAH J, Zablocki D, Sadoshima J
    The role of autophagic cell death in cardiac disease.
    J Mol Cell Cardiol. 2022;173:16-24.
    PubMed     Abstract available

    November 2022
  7. GARRY DJ, Weiner JI, Greising SM, Garry MG, et al
    Mechanisms and strategies to promote cardiac xenotransplantation.
    J Mol Cell Cardiol. 2022;172:109-119.
    PubMed     Abstract available

  8. FOWLER ED, Wang N, Hezzell MJ, Chanoit G, et al
    Improved Ca(2+) release synchrony following selective modification of Itof and phase 1 repolarization in normal and failing ventricular myocytes.
    J Mol Cell Cardiol. 2022;172:52-62.
    PubMed     Abstract available

    October 2022
  9. YANG X, Kawasaki NK, Min J, Matsui T, et al
    Ferroptosis in heart failure.
    J Mol Cell Cardiol. 2022 Oct 20. pii: S0022-2828(22)00537.
    PubMed     Abstract available

  10. HUNTER JD, Hancko A, Shakya P, Hill R, et al
    Characterization of decellularized left and right ventricular myocardial matrix hydrogels and their effects on cardiac progenitor cells.
    J Mol Cell Cardiol. 2022;171:45-55.
    PubMed     Abstract available

    September 2022
  11. JOHNSON DM, Pavlovic D
    What is actually preserved in HFpEF? Focus on myocyte calcium handling remodelling.
    J Mol Cell Cardiol. 2022;170:115-116.

  12. ZHU W, Sun J, Bishop SP, Sadek H, et al
    Turning back the clock: A concise viewpoint of cardiomyocyte cell cycle activation for myocardial regeneration and repair.
    J Mol Cell Cardiol. 2022;170:15-21.
    PubMed     Abstract available

    August 2022
  13. FU J, Li L, Chen L, Su C, et al
    PGE2 protects against heart failure through inhibiting TGF-beta1 synthesis in cardiomyocytes and crosstalk between TGF-beta1 and GRK2.
    J Mol Cell Cardiol. 2022;172:63-77.
    PubMed     Abstract available

  14. THARP CA, McKinsey TA
    Tissue is the issue: Endomyocardial biopsies to elucidate molecular mechanisms and tailor therapy for HFpEF.
    J Mol Cell Cardiol. 2022;169:111-112.

  15. GUO X, Chen Y, Liu Q
    Necroptosis in heart disease: Molecular mechanisms and therapeutic implications.
    J Mol Cell Cardiol. 2022;169:74-83.
    PubMed     Abstract available

  16. GHEBLAWI M, de Oliveira AA, Williams VR, John R, et al
    An advanced endothelial murine HFpEF model: eNOS is critical for angiotensin 1-7 rescue of the diabetic phenotype.
    J Mol Cell Cardiol. 2022;169:10-12.

    July 2022
  17. FERRERO KM, Koch WJ
    GRK2 in cardiovascular disease and its potential as a therapeutic target.
    J Mol Cell Cardiol. 2022;172:14-23.
    PubMed     Abstract available

  18. MARTENS P, Nguyen C, Tang WHW
    Is epicardial adipose tissue a key pathophysiologic target in heart failure with preserved ejection?
    J Mol Cell Cardiol. 2022;171:69-70.

  19. BODE D, Sotomayor-Flores C, Schiattarella GG
    Up next: The dawn of systems biology in HFpEF research.
    J Mol Cell Cardiol. 2022;168:96-97.

  20. WITHAAR C, Li S, Meems LMG, Sillje HHW, et al
    Aging and HFpEF: Are we running out of time?
    J Mol Cell Cardiol. 2022;168:33-34.

    A misdirected conundrum in translational HFpEF research.
    J Mol Cell Cardiol. 2022;168:1-2.

    June 2022
  22. WEERTS J, Mourmans SGJ, Eringa E, van Empel VPM, et al
    Improving insights into the heterogeneous HFpEF syndrome through microvascular research.
    J Mol Cell Cardiol. 2022;167:106-108.

  23. EMTER CA
    A 'Swine Time' for HFpEF: Multiple animal models for a myriad of clinical phenotypes.
    J Mol Cell Cardiol. 2022;167:15-16.

    May 2022
  24. CHENG G, Zhu D, Huang K, Caranasos TG, et al
    Minimally invasive delivery of a hydrogel-based exosome patch to prevent heart failure.
    J Mol Cell Cardiol. 2022 May 3. pii: S0022-2828(22)00085.
    PubMed     Abstract available

  25. KANASSATEGA RS, Bunch TA, Lepak VC, Wang C, et al
    Human cardiac myosin-binding protein C phosphorylation- and mutation-dependent structural dynamics monitored by time-resolved FRET.
    J Mol Cell Cardiol. 2022;166:116-126.
    PubMed     Abstract available

  26. ZHAO Y, Godier-Furnemont A, Bax NAM, Bouten CVC, et al
    Changes in extracellular matrix in failing human non-ischemic and ischemic hearts with mechanical unloading.
    J Mol Cell Cardiol. 2022;166:137-151.
    PubMed     Abstract available

    April 2022
  27. SEDEJ S, Abdellatif M
    Metabolic therapy for managing heart failure with preserved ejection fraction.
    J Mol Cell Cardiol. 2022;168:68-69.

  28. MOTURI S, Ghosh-Choudhary SK, Finkel T
    Cardiovascular disease and the biology of aging.
    J Mol Cell Cardiol. 2022;167:109-117.
    PubMed     Abstract available

  29. WANG C, Zhang Y, Methawasin M, Braz CU, et al
    RBM20(S639G) mutation is a high genetic risk factor for premature death through RNA-protein condensates.
    J Mol Cell Cardiol. 2022;165:115-129.
    PubMed     Abstract available

    March 2022
  30. GARBINCIUS JF, Luongo TS, Jadiya P, Hildebrand AN, et al
    Enhanced NCLX-dependent mitochondrial Ca(2+) efflux attenuates pathological remodeling in heart failure.
    J Mol Cell Cardiol. 2022;167:52-66.
    PubMed     Abstract available

  31. ABDELLATIF M, Kroemer G
    Heart failure with preserved ejection fraction: An age-related condition.
    J Mol Cell Cardiol. 2022;167:83-84.

  32. DYCK JRB, Sossalla S, Hamdani N, Coronel R, et al
    Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: Evidence for potential off-target effects.
    J Mol Cell Cardiol. 2022;167:17-31.
    PubMed     Abstract available

  33. WANG YL, Bai L, Shi XR, Zhu H, et al
    Osteoblast MR deficiency protects against adverse ventricular remodeling after myocardial infarction.
    J Mol Cell Cardiol. 2022 Mar 18. pii: S0022-2828(22)00047.
    PubMed     Abstract available

  34. QIU Y, Pan X, Chen Y, Xiao J, et al
    Hallmarks of exercised heart.
    J Mol Cell Cardiol. 2022;164:126-135.
    PubMed     Abstract available

  35. WANG N, Dries E, Fowler ED, Harmer SC, et al
    Inducing Ito,f and phase 1 repolarization of the cardiac action potential with a Kv4.3/KChIP2.1 bicistronic transgene.
    J Mol Cell Cardiol. 2022;164:29-41.
    PubMed     Abstract available

  36. TANI H, Tohyama S, Kishino Y, Kanazawa H, et al
    Production of functional cardiomyocytes and cardiac tissue from human induced pluripotent stem cells for regenerative therapy.
    J Mol Cell Cardiol. 2022;164:83-91.
    PubMed     Abstract available

    February 2022
  37. ESCHENHAGEN T, Ridders K, Weinberger F
    How to repair a broken heart with pluripotent stem cell-derived cardiomyocytes.
    J Mol Cell Cardiol. 2022;163:106-117.
    PubMed     Abstract available

  38. STENZIG J, Lemoine MD, Stoter AMS, Wrona KM, et al
    Recapitulation of dyssynchrony-associated contractile impairment in asymmetrically paced engineered heart tissue.
    J Mol Cell Cardiol. 2022;163:97-105.
    PubMed     Abstract available

    January 2022
  39. LIU X, Zhang Y, Deng Y, Yang L, et al
    Mitochondrial protein hyperacetylation underpins heart failure with preserved ejection fraction in mice.
    J Mol Cell Cardiol. 2022;165:76-85.
    PubMed     Abstract available

    November 2021
  40. CHAPSKI DJ, Cabaj M, Morselli M, Mason RJ, et al
    Early adaptive chromatin remodeling events precede pathologic phenotypes and are reinforced in the failing heart.
    J Mol Cell Cardiol. 2021;160:73-86.
    PubMed     Abstract available

    October 2021
  41. CAGGIANO LR, Holmes JW, Witzenburg CM
    Individual variability in animal-specific hemodynamic compensation following myocardial infarction.
    J Mol Cell Cardiol. 2021 Oct 28. pii: S0022-2828(21)00207.
    PubMed     Abstract available

    September 2021
  42. DAVIS K, Azarcon P, Hickenlooper S, Bia R, et al
    The role of demethylases in cardiac development and disease.
    J Mol Cell Cardiol. 2021;158:89-100.
    PubMed     Abstract available

  43. SHEN S, Sewanan LR, Campbell SG
    Evidence for synergy between sarcomeres and fibroblasts in an in vitro model of myocardial reverse remodeling.
    J Mol Cell Cardiol. 2021;158:11-25.
    PubMed     Abstract available

  44. RITTERHOFF J, McMillen TS, Villet O, Young S, et al
    Increasing fatty acid oxidation elicits a sex-dependent response in failing mouse hearts.
    J Mol Cell Cardiol. 2021;158:1-10.
    PubMed     Abstract available

    August 2021
  45. AKSENTIJEVIC D, Shattock MJ
    With a grain of salt: Sodium elevation and metabolic remodelling in heart failure.
    J Mol Cell Cardiol. 2021 Aug 6. pii: S0022-2828(21)00156.
    PubMed     Abstract available

    July 2021
  46. MASHALI MA, Saad NS, Canan BD, Elnakish MT, et al
    Impact of etiology on force and kinetics of left ventricular end-stage failing human myocardium.
    J Mol Cell Cardiol. 2021;156:7-19.
    PubMed     Abstract available

    June 2021
  47. PATEREK A, Okninska M, Chajduk E, Polkowska-Motrenko H, et al
    Systemic iron deficiency does not affect the cardiac iron content and progression of heart failure.
    J Mol Cell Cardiol. 2021;159:16-27.
    PubMed     Abstract available

  48. GARNIER A, Bork NI, Jacquet E, Zipfel S, et al
    Mapping genetic changes in the cAMP-signaling cascade in human atria.
    J Mol Cell Cardiol. 2021;155:10-20.
    PubMed     Abstract available

    May 2021
  49. YAN J, Killingsworth C, Walcott G, Zhu Y, et al
    Molecular remodeling of Cx43, but not structural remodeling, promotes arrhythmias in an arrhythmogenic canine model of nonischemic heart failure.
    J Mol Cell Cardiol. 2021 May 25. pii: S0022-2828(21)00106.
    PubMed     Abstract available

  50. IGAKI Y, Tanno M, Sato T, Kouzu H, et al
    Xanthine oxidoreductase-mediated injury is amplified by upregulated AMP deaminase in type 2 diabetic rat hearts under the condition of pressure overload.
    J Mol Cell Cardiol. 2021;154:21-31.
    PubMed     Abstract available

  51. MCCABE KJ, Rangamani P
    Computational modeling approaches to cAMP/PKA signaling in cardiomyocytes.
    J Mol Cell Cardiol. 2021;154:32-40.
    PubMed     Abstract available

    February 2021
  52. RATTKA M, Westphal S, Gahr BM, Just S, et al
    Spen deficiency interferes with Connexin 43 expression and leads to heart failure in zebrafish.
    J Mol Cell Cardiol. 2021 Feb 4. pii: S0022-2828(21)00022.
    PubMed     Abstract available

  53. HINGER SA, Wei J, Dorn LE, Whitson BA, et al
    Remodeling of the m(6)A landscape in the heart reveals few conserved post-transcriptional events underlying cardiomyocyte hypertrophy.
    J Mol Cell Cardiol. 2021;151:46-55.
    PubMed     Abstract available

    December 2020
  54. MORA MT, Gong JQX, Sobie EA, Trenor B, et al
    The role of beta-adrenergic system remodeling in human heart failure: A mechanistic investigation.
    J Mol Cell Cardiol. 2020 Dec 13. pii: S0022-2828(20)30344.
    PubMed     Abstract available

  55. MAMIC P, Chaikijurajai T, Tang WHW
    Gut microbiome - A potential mediator of pathogenesis in heart failure and its comorbidities: State-of-the-art review.
    J Mol Cell Cardiol. 2020 Dec 8. pii: S0022-2828(20)30340.
    PubMed     Abstract available

  56. CORTASSA S, Juhaszova M, Aon MA, Zorov DB, et al
    Mitochondrial Ca(2+), redox environment and ROS emission in heart failure: Two sides of the same coin?
    J Mol Cell Cardiol. 2020 Dec 7. pii: S0022-2828(20)30336.
    PubMed     Abstract available

  57. O'ROURKE B, Ashok D, Liu T
    Mitochondrial Ca(2+) in heart failure: Not enough or too much?
    J Mol Cell Cardiol. 2020 Dec 5. pii: S0022-2828(20)30337.
    PubMed     Abstract available

  58. NOMURA S, Komuro I
    Precision medicine for heart failure based on molecular mechanisms The Research Achievement Award Lecture.
    J Mol Cell Cardiol. 2020 Dec 1. pii: S0022-2828(20)30333.
    PubMed     Abstract available

    November 2020
  59. ROLLE IG, Crivellari I, Zanello A, Mazzega E, et al
    Heart failure impairs the mechanotransduction propeties of human cardiac pericytes.
    J Mol Cell Cardiol. 2020;151:15-30.
    PubMed     Abstract available

    March 2020
  60. RAZAVI AC, Bazzano LA, He J, Li S, et al
    Pseudouridine and N-formylmethionine associate with left ventricular mass index: Metabolome-wide association analysis of cardiac remodeling.
    J Mol Cell Cardiol. 2020;140:22-29.
    PubMed     Abstract available

    January 2020
  61. ALI HR, Michel CR, Lin YH, McKinsey TA, et al
    Defining decreased protein succinylation of failing human cardiac myofibrils in ischemic cardiomyopathy.
    J Mol Cell Cardiol. 2020;138:304-317.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Chronic Heart Failure is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.